Loeys–Dietz syndrome

From Self-sufficiency
Revision as of 17:19, 20 September 2010 by Rrburke (Talk) (External links)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Loeys-Dietz syndrome
Classification and external resources
OMIM below See below
DiseasesDB 34032

Loeys-Dietz syndrome is a recently-discovered autosomal dominant genetic syndrome which has many features similar to Marfan syndrome, but which is caused by mutations in the genes encoding transforming growth factor beta receptor 1 (TGFBR1) or 2 (TGFBR2).[1][2][3]

It was identified and characterized by American physician Harry C. Dietz and Belgian physician Bart L. Loeys, for whom it is named.

Types

There are currently two forms of Loeys-Dietz syndrome which are further subdivided into another two forms. The table below will better summarize this:

Type Gene Locus OMIM Description
1A TGFBR1 9q22 609192 Also known as Furlong disease
1B TGFBR2 3p22 610168
2A TGFBR1 9q22 608967
2B TGFBR2 3p22 610380 Previously known as Marfan syndrome type 2

Symptoms

The main clinical characteristics include:

  • Widely spaced eyes (orbital hypertelorism)
  • Cleft palate or bifid uvula (a split in the tissue that hangs down in the back of the throat)
  • Aortic and arterial aneurysms/dissections with tortuosity (corkscrew structure) of the arteries.

Other findings can include:

Many of the physical findings typical in Loeys-Dietz syndrome are also found in Marfan syndrome cases, including increased risk of ascending aortic aneurysm and aortic dissection, abnormally long limbs and fingers, and dural ectasia (a gradual stretching and weakening of the dura mater that can cause abdominal and leg pain). However, it also has some additional traits not typical of Marfan patients, including widely spaced eyes, a split uvula in the back of the throat, and skin findings such as easy bruising or abnormal scars.

Treatment

As there is no known cure, Loeys-Dietz syndrome is a lifelong condition. Due to the high risk of death from aortic aneurysm rupture, patients should be followed closely to monitor aneurysm formation, which can then be corrected with vascular surgery.

Previous research in laboratory mice has suggested that the angiotensin II receptor antagonist losartan, which appears to block TGF-beta activity, can slow or halt the formation of aortic aneurysms in Marfan syndrome. A large clinical trial sponsored by the National Institutes of Health is currently underway to explore the use of losartan to prevent aneurysms in Marfan syndrome patients. Both Marfan syndrome and Loeys-Dietz syndrome are associated with increased TGF-beta signaling in the vessel wall. Therefore, losartan also holds promise for the treatment of Loeys-Dietz syndrome.

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

entry on Loeys-Dietz Syndrome]

fr:Syndrome de Loeys-Dietz

id:Sindrom Loeys-Dietz

pl:Zespół Loeysa-Dietza
  1. Loeys BL, Schwarze U, Holm T; et al. (2006). "Aneurysm syndromes caused by mutations in the TGF-beta receptor". N. Engl. J. Med. 355 (8): 788–98. doi:10.1056/NEJMoa055695. PMID 16928994. 
  2. LeMaire SA, Pannu H, Tran-Fadulu V, Carter SA, Coselli JS, Milewicz DM (2007). "Severe aortic and arterial aneurysms associated with a TGFBR2 mutation". Nature clinical practice. Cardiovascular medicine. 4 (3): 167–71. doi:10.1038/ncpcardio0797. PMC 2561071Freely accessible. PMID 17330129. 
  3. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.